HOME >> BIOLOGY >> NEWS
Biosite reports on presentation of preliminary data from sepsis program

SAN DIEGO and BRUSSELS, Belgium Biosite Incorporated (Nasdaq:BSTE) today announced preliminary results of a sample collection study aimed at identifying a biomarker panel that could potentially aid in the assessment for risk of sepsis progression. Sepsis is an often fatal condition with limited therapeutic options. Clinical investigator, Emanuel P. Rivers, M.D., MPH, vice chairman and director of research at the department of emergency medicine at Henry Ford Hospital in Detroit, presented the data at the 27th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.

In this study, we identified a combination of three biomarkers that performed better when compared to several other individual biomarkers, said Dr. Rivers. This preliminary study suggests that these biomarkers may be a clinically useful tool in the assessment of risk of sepsis progression within 72 hours of patients presenting to the emergency department and meeting the diagnostic criteria for sepsis. We look forward to future studies that will be aimed at substantiating these findings.

We are encouraged by this study and will advance this sepsis biomarker panel to the next step in our clinical process, said Ken Buechler, Ph.D., Biosite president and chief scientific officer. We are on track to launch a prospective multi-center clinical study in the second quarter of 2007 to validate the clinical utility of this panel and compile data needed for an FDA submission.

The biomarkers on the panel, neutrophil gelatinase-associated lipocalin (NGAL), c-reactive protein (CRP), and macrophage inflammatory protein-3 (MIP-3), were selected from 150 biomarkers studied through the Biosite Discovery program. The panel incorporates Biosites proprietary MultiMarker Index (MMX) Value feature that uses an algorithm to generate a single quantitative result from multiple simultaneous biomarker measurements. Biosite intends to commercialize the panel of biomarkers
'"/>

Contact: Nicole Beckstrand
nbeckstrand@biosite.com
858-805-2803
Biosite Incorporated
28-Mar-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
4. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/31/2015)... , Aug. 31, 2015  For people with Down ... their day. The biotechnology company, located in the Science ... of the best potential therapies yet for people with Down ... " Correction of Down syndrome and Edwards syndrome aneuploidies ... DNA Research . Elixirgen plans to develop this ...
(Date:8/31/2015)... 31, 2015 FLX Bio, Inc., a biopharmaceutical ... cancer immunotherapies, announced today that it has appointed ... and William Ho , M.D., Ph.D., as Chief ... management team led by veterans of Flexus Biosciences, Inc., ... Scientific Officer; Jay Powers , Ph.D., Vice President, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive menstrual ... available new FDA approved system in the last 14 years, and the only endometrial ... (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... presented two studies at the International Spine Intervention Society’ s 23rd ... through to August 1st, 2015. With a focus on evidence-based research and clinical ...
Breaking Biology Technology:New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
Cached News: